Last reviewed · How we verify
fentanyl and dexmedetomindine
Fentanyl is an opioid agonist that binds mu opioid receptors for analgesia and sedation, while dexmedetomidine is an alpha-2 adrenergic agonist that provides additional sedation and analgesia with reduced respiratory depression.
The combination of fentanyl and dexmedetomidine is under investigation for sedation and analgesia in mechanically ventilated patients. This regimen aims to improve patient comfort and reduce adverse events compared to standard care.
At a glance
| Generic name | fentanyl and dexmedetomindine |
|---|---|
| Sponsor | The Affiliated Hospital of Qingdao University |
| Drug class | Opioid agonist combined with alpha-2 adrenergic agonist |
| Target | Mu opioid receptor (fentanyl); Alpha-2 adrenergic receptor (dexmedetomidine) |
| Modality | Small molecule |
| Therapeutic area | Anesthesia, Analgesia, Sedation |
| Phase | FDA-approved |
Mechanism of action
Fentanyl acts as a potent mu opioid receptor agonist, blocking pain signal transmission and producing analgesia and sedation. Dexmedetomidine selectively binds alpha-2 adrenergic receptors in the central nervous system, producing sedation, analgesia, and anxiolysis while preserving airway reflexes better than opioids alone. The combination provides synergistic analgesic and sedative effects with potentially reduced opioid requirements.
Approved indications
- Perioperative analgesia and sedation
- Procedural sedation
Common side effects
- Respiratory depression
- Hypotension
- Bradycardia
- Sedation
- Dizziness
Key clinical trials
- Effect of Different Sedation and Analgesia Strategies on Patients With Mechanical Ventilation (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: